Starting this month, members of Congress will be looking closely at U.S. spending as they work with the White House to build the 2012 budget. One area that has come under increased scrutiny is U.S. spending on global health programs. Several groups last week announced a petition (http://www.supportglobalhealth.org/) seeking support for global health spending through the United States Global Health Initiative. Many fear that even flat spending in this area could jeopardize important programs in vaccine research and treatment.
News like this highlights the important role that public-private partnerships play in supporting access to global health care. The Global Health Progress initiative seeks to bring research-based biopharmaceutical companies and global health leaders together to improve access to medicine and health care in the developing world. We are committed to being part of the effort to create a sustainable health care system that includes improving access to health care and continuing medical innovation and progress for all people.
Research-based biopharmaceutical companies and their partners around the world are working to implement sustainable solutions and strengthen the health care delivery systems so they can meet tomorrow's challenges. Millions of people lack access to essential medicines due to factors including incomplete delivery systems, lack of training for health personnel, lack of infrastructure and the cost of treatments. We must address the underlying barriers to health care, such as weak and fragmented health systems, limited health care personnel and inadequate resources for scaling up proven solutions. The innovative research and development (R&D) of new drugs and vaccines is a critical component of improving health care and combating epidemics in developing countries.
Through meaningful public-private partnerships with others in the field, including policymakers in the developed and developing world, multi-lateral institutions, non-governmental organizations, and academia we can help shape sustainable solutions that improve the health of all people.
News like this highlights the important role that public-private partnerships play in supporting access to global health care. The Global Health Progress initiative seeks to bring research-based biopharmaceutical companies and global health leaders together to improve access to medicine and health care in the developing world. We are committed to being part of the effort to create a sustainable health care system that includes improving access to health care and continuing medical innovation and progress for all people.
Research-based biopharmaceutical companies and their partners around the world are working to implement sustainable solutions and strengthen the health care delivery systems so they can meet tomorrow's challenges. Millions of people lack access to essential medicines due to factors including incomplete delivery systems, lack of training for health personnel, lack of infrastructure and the cost of treatments. We must address the underlying barriers to health care, such as weak and fragmented health systems, limited health care personnel and inadequate resources for scaling up proven solutions. The innovative research and development (R&D) of new drugs and vaccines is a critical component of improving health care and combating epidemics in developing countries.
Through meaningful public-private partnerships with others in the field, including policymakers in the developed and developing world, multi-lateral institutions, non-governmental organizations, and academia we can help shape sustainable solutions that improve the health of all people.
Tidak ada komentar:
Posting Komentar